• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sagimet Biosciences Inc. - Series A Common Stock (NQ: SGMT )

5.330 +0.180 (+3.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 842,700
Open 5.190
Bid (Size) 5.230 (3)
Ask (Size) 5.400 (1)
Prev. Close 5.150
Today's Range 5.170 - 5.539
52wk Range 2.130 - 20.71
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
November 01, 2024
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. 
Via Investor's Business Daily
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
October 29, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire

Performance

YTD
N/A
N/A
1 Month
+29.37%
+29.37%
3 Month
+83.79%
+83.79%
6 Month
+24.53%
+24.53%
1 Year
+30.64%
+30.64%

More News

Read More
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
October 16, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
October 11, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 01, 2024
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 01, 2024
Via Benzinga
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
October 01, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 01, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
September 12, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
September 04, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q2 2024
August 14, 2024
Via InvestorPlace
Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 14, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
August 01, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
June 10, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
What's Going On With Sagimet Biosciences Stock On Thursday?
June 06, 2024
Via Benzinga
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
June 06, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
June 05, 2024
Via Benzinga
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
May 16, 2024
Via Benzinga
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
May 16, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q1 2024
May 15, 2024
Via InvestorPlace
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 15, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
May 07, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
May 06, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
April 22, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
March 27, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap